Basilea Pharmaceutica AG (BSLN.SW)
CHF 41.65
(0.24%)
CHF 41.65
(0.24%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 29.49 Million CHF | 16.68% |
| 2022 | 26.21 Million CHF | 436.13% |
| 2021 | 6.72 Million CHF | 117.29% |
| 2020 | -2.23 Million CHF | -34.74% |
| 2019 | -14.12 Million CHF | 27.3% |
| 2018 | -22.75 Million CHF | -74.81% |
| 2017 | -7.3 Million CHF | 70.61% |
| 2016 | -41.67 Million CHF | 29.56% |
| 2015 | -58.83 Million CHF | -49.62% |
| 2014 | -38.92 Million CHF | -29.34% |
| 2013 | -30.57 Million CHF | 35.24% |
| 2012 | -47.2 Million CHF | 13.18% |
| 2011 | -54.37 Million CHF | -148.67% |
| 2010 | 111.71 Million CHF | 196.1% |
| 2009 | -116.24 Million CHF | 21.66% |
| 2008 | -148.38 Million CHF | -19.55% |
| 2007 | -133.76 Million CHF | -51.02% |
| 2006 | -82.18 Million CHF | -79.17% |
| 2005 | -45.86 Million CHF | 35.57% |
| 2004 | -71.18 Million CHF | -39.22% |
| 2003 | -51.13 Million CHF | 13.99% |
| 2002 | -59.45 Million CHF | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 10.15 Million CHF | 0.0% |
| 2023 Q4 | -15.96 Million CHF | 0.0% |
| 2023 Q2 | 38.65 Million CHF | 0.0% |
| 2023 FY | - CHF | 16.68% |
| 2022 Q4 | 28.32 Million CHF | 0.0% |
| 2022 Q2 | -8.68 Million CHF | 0.0% |
| 2022 FY | - CHF | 436.13% |
| 2021 Q2 | -14.95 Million CHF | 0.0% |
| 2021 Q4 | 16.88 Million CHF | 0.0% |
| 2021 FY | - CHF | 117.29% |
| 2020 Q2 | -1.32 Million CHF | 0.0% |
| 2020 FY | - CHF | -34.74% |
| 2020 Q4 | -20.73 Million CHF | 0.0% |
| 2019 Q4 | -3.2 Million CHF | 0.0% |
| 2019 Q2 | -12.35 Million CHF | 0.0% |
| 2019 FY | - CHF | 27.3% |
| 2018 FY | - CHF | -74.81% |
| 2018 Q2 | -18.52 Million CHF | 0.0% |
| 2018 Q4 | -2.88 Million CHF | 0.0% |
| 2017 Q2 | -16.65 Million CHF | 0.0% |
| 2017 Q4 | 4.41 Million CHF | 0.0% |
| 2017 FY | - CHF | 70.61% |
| 2016 Q2 | -23.64 Million CHF | 0.0% |
| 2016 FY | - CHF | 29.56% |
| 2016 Q4 | -18.02 Million CHF | 0.0% |
| 2015 Q2 | -28.78 Million CHF | 0.0% |
| 2015 Q4 | -30.36 Million CHF | 0.0% |
| 2015 FY | - CHF | -49.62% |
| 2014 Q4 | -21.18 Million CHF | 0.0% |
| 2014 FY | - CHF | -29.34% |
| 2014 Q2 | -18.35 Million CHF | 0.0% |
| 2013 Q4 | -15.03 Million CHF | 0.0% |
| 2013 Q2 | -15.53 Million CHF | 0.0% |
| 2013 FY | - CHF | 35.24% |
| 2012 Q2 | -12.17 Million CHF | 0.0% |
| 2012 Q1 | -12.17 Million CHF | 0.0% |
| 2012 Q4 | -7.56 Million CHF | 37.83% |
| 2012 FY | - CHF | 13.18% |
| 2012 Q3 | -12.17 Million CHF | 0.0% |
| 2011 FY | - CHF | -148.67% |
| 2011 Q3 | -13.55 Million CHF | 0.0% |
| 2011 Q4 | -12.17 Million CHF | 10.17% |
| 2011 Q2 | -13.55 Million CHF | 0.0% |
| 2011 Q1 | -13.55 Million CHF | 0.0% |
| 2010 Q4 | -13.55 Million CHF | -148.31% |
| 2010 FY | - CHF | 196.1% |
| 2010 Q2 | 28.05 Million CHF | 0.0% |
| 2010 Q1 | 28.05 Million CHF | 0.0% |
| 2010 Q3 | 28.05 Million CHF | 0.0% |
| 2009 FY | - CHF | 21.66% |
| 2009 Q1 | -28.81 Million CHF | 0.0% |
| 2009 Q2 | -28.81 Million CHF | 0.0% |
| 2009 Q3 | -28.81 Million CHF | 0.0% |
| 2009 Q4 | 28.05 Million CHF | 197.35% |
| 2008 FY | - CHF | -19.55% |
| 2008 Q4 | -28.81 Million CHF | 17.32% |
| 2008 Q1 | -34.85 Million CHF | 0.0% |
| 2008 Q2 | -34.85 Million CHF | 0.0% |
| 2008 Q3 | -34.85 Million CHF | 0.0% |
| 2007 Q2 | -31.02 Million CHF | 0.0% |
| 2007 Q4 | -34.85 Million CHF | -12.32% |
| 2007 Q3 | -31.02 Million CHF | 0.0% |
| 2007 Q1 | -31.02 Million CHF | 0.0% |
| 2007 FY | - CHF | -51.02% |
| 2006 Q2 | -20.54 Million CHF | 0.0% |
| 2006 Q3 | -20.54 Million CHF | 0.0% |
| 2006 Q4 | -31.02 Million CHF | -51.02% |
| 2006 FY | - CHF | -79.17% |
| 2006 Q1 | -20.54 Million CHF | 0.0% |
| 2005 Q4 | -20.54 Million CHF | -79.17% |
| 2005 Q3 | -11.46 Million CHF | 0.0% |
| 2005 Q1 | -11.46 Million CHF | 0.0% |
| 2005 Q2 | -11.46 Million CHF | 0.0% |
| 2005 FY | - CHF | 35.57% |
| 2004 FY | - CHF | -39.22% |
| 2004 Q1 | -17.73 Million CHF | 0.0% |
| 2004 Q2 | -17.73 Million CHF | 0.0% |
| 2004 Q3 | -17.73 Million CHF | 0.0% |
| 2004 Q4 | -11.46 Million CHF | 35.34% |
| 2003 Q1 | -12.72 Million CHF | 0.0% |
| 2003 Q3 | -12.72 Million CHF | 0.0% |
| 2003 Q4 | -17.73 Million CHF | -39.38% |
| 2003 Q2 | -12.72 Million CHF | 0.0% |
| 2003 FY | - CHF | 13.99% |
| 2002 Q3 | -13.9 Million CHF | 0.0% |
| 2002 FY | - CHF | 0.0% |
| 2002 Q2 | -13.9 Million CHF | 0.0% |
| 2002 Q1 | -13.9 Million CHF | 0.0% |
| 2002 Q4 | -12.72 Million CHF | 8.46% |
| 2001 Q4 | -13.9 Million CHF | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Addex Therapeutics Ltd | -10.22 Million CHF | 388.356% |
| BB Biotech AG | -201.25 Million CHF | 114.655% |
| Evolva Holding SA | -98.35 Million CHF | 129.988% |
| Idorsia Ltd | -254.55 Million CHF | 111.587% |
| Kuros Biosciences AG | -10.4 Million CHF | 383.361% |
| Molecular Partners AG | -59.51 Million CHF | 149.559% |
| Relief Therapeutics Holding AG | -108.2 Million CHF | 127.259% |
| Santhera Pharmaceuticals Holding AG | 79.17 Million CHF | 62.747% |